After six months of negotiations, pharmaceutical company Sanofi-Aventis has agreed to buy biotechnology company Genzyme Corporation in a deal valued at approximately $20.1 billion.
Genzyme shareholders will receive $74 per share in cash, up from an initial bid in August of $68. Additionally, each Genzyme shareholder will be entitled to up to an additional $14 per share based on the performance of blood cancer drug Lemtrada and rare disease treatments Cerezyme and Fabrazyme.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
